ONDO - Ondo InsurTech PLC
Executive Summary
Ondo InsurTech PLC is a UK-listed technology company focused on sustainable risk reduction for the insurance sector, deploying connected leak-detection devices and associated software to help insurers cut escape-of-water claims. Its flagship LeakBot solution is sold to UK and US home insurers, which then offer the device to policyholders as a loss-prevention service, positioning Ondo as a specialist insurtech vendor rather than a generalist software provider.
The investment case rests on the FY26 results, which showed recurring revenue growth of 51%, contracted annual recurring revenue of GBP 6.8m, US revenue up 117% and active LeakBots rising 33%. What has to go right is the maturation of the US cohort to a level that supports EBITDA break-even without further margin compression from device deployment costs. The primary risk is that device-related cost growth continues to outpace recurring revenue, prolonging operating losses.
BUY. Conviction Score: 66/100. The view would be downgraded if the next interim update showed US cohort unit economics deteriorating materially, or if a dilutive equity raise were used to fund device inventory rather than partner financing.
Business Model
Ondo generates revenue primarily through the sale or placement of LeakBot devices with insurer partners, with the bulk of that revenue now classified as recurring under the FY26 disclosure. The contracted annual recurring revenue base stood at GBP 6.8m at the FY26 results, supported by an active installed base of LeakBots that grew 33% year-on-year, indicating that the economic model is increasingly subscription-like rather than purely transactional hardware sales.
Customers are UK and US home insurers that distribute the LeakBot to policyholders as a risk-mitigation service. The company's website confirms results publications covering the period to end September 2025, and the FY26 announcement highlighted a 117% increase in US revenue, suggesting the US book is the principal growth engine and is taking share within the customer mix.
The competitive moat is the combination of proprietary leak-detection hardware, the data set accumulated across an expanding installed base, and the insurer-channel relationships required to embed LeakBot into policy propositions. Reported EPS of minus 0.05 and widening operating losses indicate the model is not yet self-funding, and FY26 flagged margin compression risk from device deployment costs, so pricing power remains unproven until unit economics on the US cohort are disclosed.
Financial Snapshot
Recent Catalysts
[May 2026] - Ondo InsurTech announced an expansion of its all-employee Share Incentive Plan, with directors increasing their stakes through the enlarged programme. Source: Insurance Nerds Editorial Team (insnerds.com), 6 May 2026.
[1 May 2026] - The company received notification from Fiduchi Trustees Limited (UK), acting as SIP Trustee, regarding a Share Incentive Plan purchase involving Ondo InsurTech PLC shares. Source: InvestEgate RNS Announcement, 1 May 2026.
[FY26 results, period to end September 2025] - Full-year results reported 51% recurring revenue growth, contracted ARR of GBP 6.8m, US revenue up 117% and active LeakBots up 33%, alongside EPS of minus 0.05 and continuing operating losses. Source: Ondo InsurTech PLC company website (ondoplc.com).
[April-May 2026] - The shares set fresh 52-week lows on elevated volume, with reports of prints at GBX 3.50 and closes around GBX 3.73 to GBX 3.85 in late April and early May 2026. Source: Daily Political, 29 April 2026; Stock Observer, 5 May 2026.
Thesis Evaluation
Bull Case (33% weight)
The US cohort matures on insurer partner books faster than the FY26 trajectory suggests, recurring revenue compounds at a similar or stronger rate than the 51% reported, and the company reaches EBITDA positivity without a dilutive raise. Under those conditions the shares could revisit the upper end of the 52-week range. Bull target: 28.00p, 12-month horizon.
Base Case (51% weight)
The installed base continues to grow in the 30-40% range, ARR scales towards GBP 9m, and US revenue keeps expanding while UK remains the cash engine. EPS stays negative but the operating loss narrows as device cost drag moderates. Base target: 14.00p, 12-month horizon.
Bear Case (16% weight)
Device deployment costs continue to compress margins faster than recurring revenue scales, the US cohort fails to mature within the assumed timeline, and a dilutive placing is required to fund inventory. The shares retest the recent 52-week low area. Bear target: 3.00p, 12-month horizon.
Key Risks
- US cohort unit economics underperformance: If US LeakBot unit economics fail to mature as expected, recurring revenue growth could decelerate sharply and device deployment costs would compound margin compression already flagged in the FY26 disclosure. Estimated probability: 35%. Impact: severe.
- Margin compression from device costs: FY26 results explicitly highlighted margin compression risk from device deployment costs, which could prolong operating losses and delay any path to EBITDA break-even. Estimated probability: 45%. Impact: moderate.
- Dilutive equity issuance: Continued cash burn with negative EPS of minus 0.05 may force a placing or other dilutive raise to fund device inventory and US expansion, impairing per-share value. Estimated probability: 30%. Impact: moderate.
- Insurer partner concentration: Revenue depends on a small number of UK and US home insurer partners; loss or repricing of a key account would materially impair the recurring revenue base. Estimated probability: 25%. Impact: severe.
- Liquidity and going-concern risk: Persistent operating losses and widening cash outflows raise the risk that working capital becomes constrained before the recurring model reaches self-funding. Estimated probability: 20%. Impact: severe.
- Share price weakness and momentum risk: The shares printed fresh 52-week lows in April and May 2026 on elevated volume, which can trigger forced selling by momentum and algorithmic participants irrespective of fundamentals. Estimated probability: 50%. Impact: low.
Who Should Own It / Avoid It
Ideal for: growth-oriented investors with a high risk tolerance and a minimum 18-24 month holding horizon who can tolerate negative EPS and an unprofitable operating model in pursuit of ARR-led scaling, and who want targeted exposure to a niche UK-listed insurtech vendor with a defined US growth engine.
Avoid if: you require current profitability or positive EPS, need liquidity within 12 months, are unable to stomach fresh 52-week lows and multi-bagger drawdown risk, or prefer cash-generative, dividend-paying software businesses over pre-profitability growth stories.
Recommendation
BUY - 66/100. The tier reflects a barbell of strong hard-catalyst evidence from FY26 (51% recurring revenue growth, GBP 6.8m contracted ARR, 117% US expansion, +33% active LeakBots) set against unconfirmed analyst commentary, negative EPS of minus 0.05 and disclosed margin compression risk from device costs. The call would be upgraded if the next interim update demonstrates US cohort unit economics approaching break-even and a clear path to EBITDA positivity without dilution. It would be downgraded on any indication of a dilutive raise, an ARR deceleration below 30%, or a material US partner loss. At the current price of 8.26p the shares trade above our buy ceiling of 6.67p: the thesis is credible but the price is not - new positions only below that level.
The probability-weighted value across our three scenarios is 16.86p, 104% above the current price of 8.26p - the market has not yet priced our probability-weighted view. Levels below are derived from the scenario targets and probabilities above, not from percentage offsets to today's price.
below 6.67p - below this level the upside to the base-case target (14.00p) is at least 2x the downside to the bear case (3.00p), the minimum risk/reward we require before committing new capital.
between 6.67p and 14.00p - the base case is not yet fully priced, so existing holders are paid to wait, but new money gets no margin of safety in this zone.
above 14.00p - at this level the base case is fully reflected in the price and anything beyond it is paying for a bull scenario we weight at 33%.
if any dilutive equity raise to fund device inventory, or a recurring revenue growth print below 30% at the next interim update, combined with continued widening of operating losses, regardless of price - the bear target of 3.00p is the backstop, not an arbitrary percentage stop.
Conviction Trend
Latest conviction: 66/100. Trend versus prior report: Flat.
| Report date | Conviction |
|---|---|
| 2026-08-01 | 29 |
| 2026-07-25 | 29 |
| 2026-06-28 | 29 |
| 2026-05-30 | 40 |
| 2026-04-27 | 81 |
Sources
Market data: DYOR HQ proprietary market data workflow.
Public sentiment and news flow: Public news flow drawing on regulatory announcements (RNS via InvestEgate), company investor relations materials hosted on the corporate website, insurance trade press, and third-party stock analysis coverage of share-price action and trading volume.
Primary source types: Regulatory announcements (RNS via InvestEgate), company press releases and investor relations materials on ondoplc.com, trade and financial press coverage, and third-party equity analysis commentary on fundamentals and price action.
Key sources
- Results for the Year Ended 31 March 2026 | Company Announcement
- Annual Report & Statements - Ondo Insurtech plc (ONDO)
- Ondo InsurTech (ONDO) Stock Forecast & Price Target
- Ondo InsurTech PLC (ONDO) Stock, Price, News, Quotes, ...
- ONDO.L Ondo InsurTech Plc
- Ondo - Sustainable Risk Reduction
- Top Ondo InsurTech Alternatives, Competitors
- Ondo InsurTech PLC (ONDO) Future Performance Analysis
- Access Denied
Data correct as of 2026-08-01.